UNSPSC 51343108: Fialuridine

This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H10FIN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53T7IN77LC, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo- but generally known as fialuridine, which bears US NIH Compound Identifier 50313. European Medicines Agency schedules Fialuridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07622MIG.

UNSPSC 51343108 Fialuridine, a Commodity code, does not align with recent state and local procurement activity. The code nominally identifies a specific antiviral pharmaceutical, but the four most recent opportunities posted under or near this classification describe procurement of naloxone and drug deactivation systems, general medical and first aid supplies for first responders, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription fulfillment capabilities — none of which involve fialuridine as a named product or service line. State and local buyers posting under this code appear to be public health agencies, fire departments, and health and human services commissions procuring broad pharmaceutical and medical supply categories rather than fialuridine-specific procurement.

The issuing bodies include a county health department (Seminole County, Florida), a city fire department (Tampa), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota Department of Administration and including Oregon). Geographic activity spans Florida, Texas, Minnesota, and Oregon across the recent record. Representative opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023), the City of Tampa's ITB for medical and first aid supplies for the Fire Department Rescue Division (169 line items, estimated contract amount $700,000.00, due March 13, 2026), the Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (proposals due March 26, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026). The code shows little relevant recent activity tied to fialuridine procurement specifically.